Sign up USA
Proactive Investors - Run By Investors For Investors

Aviragen tanks as trial of asthma treatment flops

Aviragen says its trial of asthma treatment vapendavir has failed to meet its primary endpoint.
Aviragen tanks as trial of asthma treatment flops
Aviragen announces results of vapendavir trial

Aviragen Therapeutics (NASDAQ:AVIR) was on the back foot on Tuesday after reporting “disappointing” results for a trial of its asthma treatment, vapendavir.

The NASDAQ-listed drug maker said the Sptiritus phase 2b trial study of vapendavir in treating moderate to severe asthma sufferers with a rhinovirus infection did not meet its primary endpoint.

The treatment failed to demonstrate a “statistically significant” reduction in asthma symptoms at day 14 of the study for the 264 mg or 528 mg dosages, compared to placebo.

“We are disappointed that the Spirtus trial did not meet its primary endpoint in this patient population,” chief executive Joseph Patti, said.

“There was evidence of an antiviral effect in patients that received vapendavir within the first day following the onset of their symptoms, and as such, we plan to take time to fully analyse the data before making a decision on whether to initiate a study in hematopoietic stem cell transplant patients, where the ability to stop the progression of the rhinovirus infection could be beneficial.” 

In early February, Aviragen reported that BTA 585, its drug for the treatment of respiratory syncytial virus infections, flunked in a phase 2a trial.

Shares plunged 34.91% on the NASDAQ in early US trade. 

Register here to be notified of future AVIR Company articles
View full AVIR profile View Profile

Related Articles

May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use